Pharmaceuticals Financial News

In a written reply to the Lok Sabha, Minister of State for Commerce and Industry Jitin Prasada said that as on date, reciprocal tariffs have not been applied by the US on India. He said that the government continues to engage with the US to achieve enhancement and broadening of bilateral trade ties in a mutually beneficial and fair manner. “Both countries plan to negotiate a mutually beneficial, multi-sector Bilateral Trade Agreement. Both countries would focus on increasing market access, reducing tariff and non-tariff barriers, enhancing supply chain integration and resolving bilateral trade issues,” Prasada said. In a separate reply, he said recently, the government has not taken any such steps to lift ban on import of certain prohibited and restricted products from USA, China and UK.

Shares of J B Chemicals & Pharmaceuticals Ltd.(up 3.03 per cent), Gland Pharma Ltd.(up 1.48 per cent), Mankind Pharma Ltd.(up 1.1 per cent), Ajanta Pharma Ltd.(up 0.23 per cent) and Abbott India Ltd.(up 0.1 per cent) ended the day as top gainers in the pack.

Subscribe to enjoy similar stories. NEW DELHI : India is advancing negotiations on a Bilateral Trade Agreement (BTA) with the US—what would typically be called a free trade agreement (FTA)—but a critical gap in Washington’s trade framework threatens to complicate the deal. Unlike past trade agreements, any pact India finalizes could face prolonged scrutiny and potential amendments by US lawmakers, as the country currently lacks Fast Track Trade Authority (FTTA)—a mechanism that allows the US president to negotiate trade deals and present them for a simple up-or-down vote in Congress.

Novo Nordisk A/S agreed to pay United Laboratories International Holdings as much as $2 billion for a next-generation obesity drug, the Danish Ozempic maker's latest move to refill its pipeline of experimental treatments. Novo will pay Hong Kong-based United Laboratories $200 million upfront for the drug, which combines three different mechanisms in an effort to treat obesity as well as diabetes and other diseases, the companies said Monday. Novo agreed to pay as much as $1.8 billion if the drug reaches certain development and sales goals. The deal comes amid growing skepticism from investors that Novo's next-generation portfolio will be sufficient to keep it on top of the hypercompetitive market for weight loss treatments. German software developer SAP SE unseated Novo as Europe's most valuable public company on Monday. Novo's shares traded down as much as 3.1% in Copenhagen. United Laboratories will retain rights in China for its compound, which works in a similar way to Novo rival Eli Lilly & Co.'s retatrutide — considered the strongest among the next-generation drugs currently in late-stage human trials.

Delhi High Court on Monday rejected Swiss multinational F. Hoffmann-La Roche AG’s petition seeking to temporarily restrain Natco Pharma from infringing its product patent for Risdiplam compound used for treating spinal muscular atrophy. The court noted that the Roche’s approved drug Risdiplam, which is marketed under the name ‘Evrysdi,’ is not available at an affordable prices, thus the public interest would be to outweigh the need for grant of injunction (restraint order). Roche had sought interim injunction against Natco Pharma to restrain infringement of its patent titled «compounds for treating spinal muscular atrophy». The multinational company claimed that its suit patent has a term of 20 years from May 11, 2015 and expires on May 11, 2035.

Production-Linked Incentive (PLI) schemes for ten sectors, including electronics and pharma, since the launch of the support measure to boost domestic manufacturing, an official statement said on Saturday. In 2021, the government announced Production-Linked Incentive (PLI) schemes for 14 sectors like telecommunication, white goods, textiles, manufacturing of medical devices, automobiles, speciality steel, food products, high-efficiency solar PV modules, advanced chemistry cell batteries, drones, and pharma, with an outlay of Rs 1.97 lakh crore. «The incentive amount of around Rs 14,020 crore disbursed under PLI schemes for 10 sectors,» the commerce and industry ministry said.

capital markets regulator Sebi to raise Rs 550 crore through an initial public offering (IPO). The proposed IPO comprises a fresh issue of equity shares worth Rs 300 crore and an offer for sale (OFS) of Rs 250 crore by promoters and promoter group entities, according to the draft red herring prospectus (DRHP) filed on Thursday. At present, promoters and promoter group entities hold 100 per cent stake in the company.

As many hospitals are planning to double their capacity over the next three to five years, Shibani Kurian, Head — Equity Research and Fund Manager, Kotak Mahindra AMC, estimates that the growth of hospital companies will outpace that of diagnostics and pharmaceutical companies. In this interview with ET Markets, Kurian also talks about investing in pharma stocks amid Trump's tariff threats. Edited excerpts from a chat:

Subscribe to enjoy similar stories. Foreign institutional investors (FIIs) have been shifting their focus from large-cap stocks to select smaller companies, reshaping investment patterns in the Indian market. In the December 2024 quarter, FIIs increased their stake in only nine Nifty 50 firms while trimming positions in the rest.

free trade agreement, after it was stalled in 2015 following their failure to narrow differences in sensitive areas including dairy and agriculture. India and New Zealand began negotiating the Comprehensive Economic Cooperation Agreement (CECA) in April 2010 to boost trade in goods, services, and investment but the talks stalled after nine rounds of discussions. The ninth round of negotiation was held in 2013. The two nations announced the launch of negotiations for a comprehensive and mutually beneficial India-New Zealand Free Trade Agreement (FTA) on the eve of the bilateral meeting between the Prime Minister Narendra Modi and Christopher Luxon, Prime Minister of New Zealand. Luxon is here on a four-day visit from March 16.

Zydus Pharmaceuticals are recalling products in the US market due to manufacturing issues, according to the US Food and Drug Administration (USFDA). The New Jersey-based Sun Pharmaceutical Industries, Inc is recalling 9,840 bottles of Morphine Sulfate extended-release tablets for «Failed Dissolution Specifications», the US health regulator stated in its latest Enforcement Report. The company initiated the Class II nationwide (US) recall on February 6, 2025. USFDA stated that Zydus Pharmaceuticals (USA) Inc is recalling a lot of Nelarabine Injection, used in the treatment of certain cancers, in the US.

IPO comprises fresh issue of equity shares aggregating up to Rs 190 crore and an offer for sale (OFS) of 71.55 lakh equity shares by promoters, according to the draft red herring prospectus (DRHP). Those selling shares in the OFS are Kantilal Ramanlal Patel and Manisha Bipin Patel.

China though it has not got the sensational public attention the AI model received. China’s biotech research is redrawing the global map. The axis of innovation is tilting from the West to Beijing. Scores of small biotech startups, which have sprung up across China over the last decade, are coming up with medical breakthroughs. Impressed by the speed of drug research and new treatment modalities, global pharmaceutical companies are throwing princely sums to buy leads, which have the potential to be drugs. There is a big lesson or two here for India, which has been prioritising generics over innovation. The quiet change in China is stark. Barely two decades ago, it was looked down as a big factory for low-cost production of chemicals and raw materials for the pharmaceutical industry. Now savvy and young scientists, trained in the US and Europe, are regrouping in their home turf. Popularly referred to as sea turtles (which return from the sea to the beach to lay eggs), they come back with their knowledge of science and business. This disruption has become an existential risk for the centuries-old, entrenched American and European pharmaceutical industries.

White House took a lighthearted turn when President Trump became distracted by JD Vance.

Subscribe to enjoy similar stories. Sun Pharmaceutical Industries Ltd’s latest acquisition of US-based Checkpoint Therapeutics, Inc. is good news for its speciality business–an area of focus.

Axis Securities has an overweight call on Lupin with a target price of Rs 2500. The current market price of Lupin Ltd. is Rs 1959. Lupin, incorporated in 1983, is a Large Cap company with a market cap of Rs 90156.51 crore, operating in the Pharmaceuticals sector. Lupin's key products/revenue segments include Pharmaceuticals, Other Services, Export Incentives, Other Operating Revenue and Scrap for the year ending 31-Mar-2024.

generic drugs to a higher risk of serious side effects in the US has drawn backlash from the industry’s most influential lobby group, as India moves to defend its dominant market share amid trade tensions under President Donald Trump. The study, which analyzed more than 2,400 drugs sold in the US between 2009 and 2018, found that Indian generics were associated with a 54% greater risk of serious adverse events — including hospitalization, disability, and death — compared with equivalent domestically made medicines. The research links operations and supply chain issues in the manufacturing process as “most likely” explaining the findings. Published last month in the journal Production and Operations Management, the findings prompted a three-page statement from the Indian Pharmaceutical Alliance, which represents two dozen of the country’s largest drugmakers.

Subscribe to enjoy similar stories. A blockbuster diabetes drug will soon be available to Indian patients at a tenth of its cost, as its patent expires. At least four Indian generics players have launched cheaper variants of the drug, which is used to treat type-2 diabetes as well as heart and kidney ailments.

employee benefits to address evolving workforce needs and attract talent amid a changing employment landscape. Organisations are now focusing on flexible health insurance, mental health support, and diversity, equity, and inclusion (DEI) measures, according to The Future of Benefits 2024 report by Mercer Marsh Benefits. The report, accessed by TOI's Rupali Mukherjee, highlights a 300% rise in companies offering flexible health insurance over the past five years. These plans now include coverage for parents, siblings, wellness programs, and financial planning tools. The study analysed data from over 10,000 policies and more than 600 benefit evaluations across 14 industries. Employees are increasingly seeking more control over their benefits, driving demand for customisable insurance and wellness schemes. The banking, financial services, and insurance (BFSI) sector offers the highest sum insured, followed by pharmaceutical and IT/ITES/e-commerce industries. Notably, 73% of IT/ITES/e-commerce firms offer insurance covering employees, spouses, children, and parents/in-laws by default, compared to 64% in pharma and 54% in manufacturing, the report noted.

Zydus Lifesciences said on Tuesday it will acquire an 85.6% stake in France's Amplitude Surgical for 256.8 million euros (nearly $280 million) as part of its plans to expand further in the global medical devices market. The acquisition, which is a nearly 81% premium to Amplitude's last close, comes as India's pharmaceutical industry is bracing itself for U.S. President Donald Trump's plans to tax pharmaceutical imports. The United States is Zydus Lifesciences's biggest market, accounting for 47% of total revenue, followed by India.

Shares of Alkem Laboratories Ltd.(up 3.14 per cent), Sun Pharmaceutical Industries Ltd.(up 2.72 per cent), Laurus Labs Ltd.(up 2.72 per cent), Zydus Lifesciences Ltd.(up 0.69 per cent) and Divi's Laboratories Ltd.(up 0.59 per cent) ended the day as top gainers in the pack.